In this respect, the combination of KLF9 inhibitors and conventional chemotherapy drugs may improve the sensitivity of cancer cells to treatment, especially in malignancies where KLF9 promotes tumor survival and proliferation. The gene discussed is KLF9; the disease is neoplasm.